2024-512495-35-00招募中3 期
Adjuvant treatment with Pramipexole for anhedonia symptoms in depression - PRIME-PRAXOL
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Region Skane
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- SHAPS-C (total SHAPS-C scores at baseline, week 3, week 6 and week 9).
研究概览
简要总结
Will treatment with pramipexole at the highest possible dosage (without intolerable adverse reactions, max 3.15 mg base) reduce anhedonia symptoms over a nine-week period compared to placebo treatment?
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 years ≤75 years.
- •Diagnosis of unipolar depressive episode, bipolar disorder in depressive phase, or dysthymia.
- •Anhedonia symptoms: 3 or 4 points on ≥ 3 items of the Snaith-Hamilton Pleasure Scale (SHAPS-C).
- •Ongoing treatment with at least one antidepressant or mood stabilizing medication ≥ 4 weeks.
- •Has tried an antidepressant at a therapeutic dose but not achieved remission (refractory stage 1 depression).
- •The research subject has given informed consent to participate in the study.
排除标准
- •Pregnancy, breastfeeding or planned pregnancy (if female).
- •Recently started psychotherapy (within 6 weeks) or planning to start such treatment during participation in the trial.
- •Ongoing or planned ECT, ketamine or rTMS treatment, excluding maintenance ECT, ketamine or rTMS (Maintenance treatment is defined as the use of ECT/ketamine/rTMS for a period exceeding 3 months after a series of ECT/ketamine/rTMS treatment in order to prevent the onset of a new episode).
- •Other medical conditions or other concomitant drug treatment which, in the opinion of the investigators, may affect the evaluability of the trial or conditions that increase trial risk. For example, Parkinson's disease, hepatic insufficiency, ongoing cancer not in remission for more than one year, bariatric surgery with a known impact on absorption of extended-release tablets.
- •Known or suspected allergy to any active substance or excipient in the medicinal product included in the trial.
- •Participation in other treatment studies.
- •Other reason, as assessed by the investigator, that prevents the research subject's participation, such as the risk that the research subject is unable to complete the trial (non-compliance).
- •High suicide risk according to the overall clinical assessment of the research physician.
- •Ongoing substance abuse (within 6 months).
- •Diagnosis of current psychosis.
- •Known diagnosis of Emotionally Unstable Personality Disorder.
- •Treatment under LPT.
- •History of or a strong clinical suspicion of impulse control disorder (including current bingeeating disorder) or a current ADHD diagnosis with hyperactivity.
- •Diagnosis of intellectual disability, dementia, or other circumstance that makes it difficult to understand the meaning of participating in the trial and give informed consent.
- •Diagnosis of renal failure (eGFR < 50 ml/min/1,73 m2) or severe cardiovascular disease (specifically symptomatic heart failure NYHA Class II or higher).
结局指标
主要结局
SHAPS-C (total SHAPS-C scores at baseline, week 3, week 6 and week 9).
SHAPS-C (total SHAPS-C scores at baseline, week 3, week 6 and week 9).
次要结局
- HDRS6 scores (subscale of HDRS-17).
- Number of steps/day, movement pattern distribution over the day, walking distance, time spent in light, moderate and intense physical activity, resting heart rate, blood oxygen saturation, heart rate variability (stress scores), sleep latency, sleep awakening, wakefulness, time in deep sleep, sleep efficiency. All variables are measured using activity meters.
- Total scores of DARS-SV-MOD, MADRS, AES, Insomnia Severity Scale GAD-7 and BBQ.
- BOLD activity in the nucleus accumbens during fMRI (MID task).
- Biomarkers related to dopamine and inflammation, measured in blood and CSF. BOLD activity in the nucleus accumbens during MID task fMRI and connectivity during diffusion tensor imaging.
- Gathering of adverse events.
- Neuropsychological test battery consisting of WAIS-IV, RBANS, D-KEFS, CPT-3 and cognitive self-assessment PDQ-5.
- The test Probabilistic Reward Task (PRT)
研究者
Daniel Lindqvist
Scientific
Region Skane
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Adjuvant treatment with Pramipexole for anhedonia symptoms in depression - PRIME-PRAXOMajor depressionMedDRA version: 20.0Level: PTClassification code: 10002511Term: Anhedonia Class: 100000004873CTIS2024-512495-35-00Region Skane140
已完成
不适用
Adjunctive treatment with pramipexole for antipsychotic-induced hyperprolactinemia in patients with schizophrenia, Reserch for efficacy and tolerability.schizophreniaJPRN-UMIN000006556Department of Neuropsychiatry,University of Fukui20
已完成
3 期
Pramipexole for Anhedonic DepressionPsychiatric Disorders MoodAnhedoniaDepressionNCT05355337Region Skane85
进行中（未招募）
1 期
Pramipexole augmentation to target anhedonia in depression - a pilot studyDepressionEUCTR2019-001907-19-SERegion Skåne15
已完成
不适用
Pramipexole and Emotional ProcessingEmotionsMotivationRewardDopamineNCT03681509University of Oxford43